CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后广泛性脊髓炎伴嗜酸性粒细胞性脑膜炎
英文原题：Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy.
查看英文原题
Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫效应细胞相关神经毒性综合征（ICANS）是CAR-T 细胞治疗后的常见不良事件。一名因难治性套细胞淋巴瘤接受抗CD19 CAR-T 治疗的患者，在输注后第8天出现广泛脊髓炎。患者脑脊液中还发现异常嗜酸性粒细胞增多。接受甲泼尼龙和siltuximab治疗后，临床症状和磁共振成像病灶均减少。这一CAR-T 治疗后嗜酸性粒细胞性脑膜炎的罕见表现，凸显了深入了解ICANS病理生理机制的必要性，尤其需要识别可靶向的通路。
展开英文摘要原文
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a frequent adverse event after Chimeric antigen receptor T cells (CAR-T cells). A patient treated with anti-CD19 CAR-T cells for a refractory mantle cell lymphoma presented at Day 8 post-infusion with extensive myelitis. Unusual eosinophilia was disclosed in the patient's cerebrospinal fluid.
After treatment with methylprednisolone and siltuximab, a decrease in clinical symptoms and magnetic resonance imaging lesions were obtained. This unprecedented presentation of eosinophilic meningitis after CAR-T cells therapy highlights the need for a better understanding of the physiopathology of ICANS, especially to identify potentially targetable pathways.
论文信息
- 作者
- Le Calvez B、Eveillard M、Decamps P、Aguilar J、Seguin A、Canet E、Grain A、Touzeau C
- 单位
- Department of Hematology Nantes University hospital Nantes France.France
- 文献类型
- 病例报告
- 期刊
- EJHaem2022 May
- 原文标识
- PubMed 35846023 · DOI 10.1002/jha2.381
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →